Hass (450330) Fundamentals 2026 — P/E 24.7x, Revenue Analysis | SniperIQ
Hass (450330) is a KR-listed Healthcare company in Medical - Specialties with a market capitalization of ₩33.7B, trading at ₩4300.00 on the KOE. This SniperIQ fundamentals page covers Hass's valuation (P/E 24.7x, P/B 0.8x), profitability (net margin 8.5%), revenue (₩16.6B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Hass's market cap?
Hass (450330) has a market capitalization of approximately ₩33.7B, trading at ₩4300.00 on the KOE. Market cap moves with the live share price.
What is Hass's P/E ratio?
Hass's trailing twelve-month P/E ratio is 24.7x, with a price-to-book (P/B) of 0.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Hass?
Hass runs a net profit margin of 8.5%, a gross margin of 49.4%, and an operating margin of -9.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Hass generate?
Hass reported revenue of ₩16.6B for fiscal year 2025, with net income of ₩1.5B and earnings per share (EPS) of 193.9. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Hass pay a dividend?
Hass offers a trailing dividend yield of about 1.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Hass financially healthy?
Hass carries a debt-to-equity ratio of 0.16x and a current ratio of 3.22x, with a market beta of 0.09. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Hass a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Hass (450330) the key facts are: market cap ₩33.7B, P/E 24.7x, revenue ₩16.6B, 52-week range 4010-8700. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Hass's full fundamentals live
Get Hass's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.